The Bob Harrington Show - Episode 25: Platelet responsiveness to antiplatelet therapy with Dr Paul Gurbel

Summary: There has been much research, press, and some controversy in the rapidly evolving sphere of antiplatelet therapy—culminating in the FDA's black-box warning on clopidogrel. Dr Paul Gurbel joins the show to clarify the core issues; review key terms such as hypo- and hyper-responsiveness and resistance and nonresponsiveness; discuss the roles and relative importance of genotyping vs phenotyping; and ponder how the GRAVITAS and TRIGGER PCI trials may help to lead the way forward for antiplatelet therapy. What are your thoughts on the FDA's black-box warning on clopidogrel? What roles do you see for genotyping and phenotyping for platelet responsiveness?